Why the study?
Does PVI with FIRM mapping improve long-term outcomes compared to PVI alone in patients with atrial fibrillation?
Does PVI with FIRM mapping improve long-term outcomes compared to PVI alone in patients with atrial fibrillation?
The addition of FIRM mapping to PVI does not provide therapeutic benefit over PVI alone for atrial fibrillation, suggesting a need to reevaluate its clinical use.
No benefit of PVI+FIRM over PVI alone in AF; challenges FIRM adoption and reinforces PVI optimization in practice and trials.
The overall pooled estimate did not show any therapeutic benefit of PVI+FIRM approach over PVI alone, which suggests the need to reevaluate the clinical use of FIRM ablation in atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Mohanty et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: